<?xml version="1.0"?>
<!DOCTYPE TimeML SYSTEM "TimeML.dtd">
<TimeML>
HealthCare Royalty Partners Announces New Chief Medical Officer, Senior-Level Promotions, and Further Regional Expansion Business Wire India 
 
HealthCare Royalty Partners ("HCR") announced several firm developments: 
 
New Chief Medical Officer: 
 
As of <TIMEX3 tid="t3" type="DATE" value="2017-01">January 2017</TIMEX3>, Dr. Warren Cooper has assumed the role of Managing Director and Chief Medical Officer at HCR. Dr. Cooper initially joined the team in <TIMEX3 tid="t4" type="DATE" value="2016">2016</TIMEX3>, consulting as an Industry Advisor. Dr. Cooper is a UK-trained physician with <TIMEX3 tid="t6" type="DURATION" value="P35Y" mod="MORE_THAN">over 35 years</TIMEX3> of experience in the global pharmaceutical industry. HCR's senior professionals have known Dr. Cooper for <TIMEX3 tid="t8" type="DURATION" value="P1DE" mod="MORE_THAN">over a decade</TIMEX3>, working closely with him when he served as CEO of Prism Pharmaceuticals ("Prism"), a portfolio company at their prior firm. Prism was a specialty pharmaceutical company that developed the antiarrhythmic agent NEXTERONE, and was ultimately acquired by Baxter International in <TIMEX3 tid="t10" type="DATE" value="2011">2011</TIMEX3> for $338 million. Prior to serving as CEO of Prism, Dr. Cooper spent <TIMEX3 tid="t12" type="DURATION" value="P12Y">12 years</TIMEX3> with Merck, initially as a UK clinical research physician, then as head of European and subsequently Worldwide Clinical Research Operations. Dr. Cooper also previously led AstraMerck's (<TIMEX3 tid="t13" type="DATE" value="PRESENT_REF">now</TIMEX3> AstraZeneca PLC) cardiovascular division. HCR looks forward to drawing on Dr. Cooper's tremendous clinical, regulatory and operational experience as it evaluates new investment opportunities. 
 
Investment Professional Promotions: 
 
HCR has promoted John Urquhart to a Principal of the firm. Mr. Urquhart was among the first employees at HCR, joining the firm as an analyst in <TIMEX3 tid="t14" type="DATE" value="2007">2007</TIMEX3> and re-joining in <TIMEX3 tid="t15" type="DATE" value="2012">2012</TIMEX3> after receiving his M.B.A. from The Wharton School of the University of Pennsylvania. Mr. Urquhart has <TIMEX3 tid="t17" type="DURATION" value="P1DE" mod="MORE_THAN">over a decade</TIMEX3> of healthcare investing experience in the royalty and structured finance market. 
 
HCR has also promoted Anthony Rapsomanikis to Vice President. Mr. Rapsomanikis joined HCR as an Associate in <TIMEX3 tid="t19" type="DATE" value="2012">2012</TIMEX3>, and was promoted to Director of West Coast Business Development after establishing the firm's San Francisco office in <TIMEX3 tid="t20" type="DATE" value="2015">2015</TIMEX3>. The San Francisco office launched HCR's strategic initiative to regionalize its business development efforts and better serve the needs of counterparties in key geographic areas. 
 
"John and Tony's promotions are well deserved and serve as recognition of their growth and contributions to the firm <TIMEX3 tid="t22" type="DURATION" value="PXY" mod="MORE_THAN">over the past several years</TIMEX3>," commented Clarke Futch, co-founder and Chairman of the Investment Committee at HCR. 
 
Regional Office Expansion: 
 
HCR is pleased to announce its plans to open a Boston, MA office in <TIMEX3 tid="t23" type="DATE" value="2017-H1">the first half of 2017</TIMEX3>, which will be led by John Urquhart. Mr. Urquhart will work closely with Clarke Futch, Paul Hadden (Managing Director - Business Development) and the rest of the senior investment team, most of whom will continue to be based in the firm's headquarters in Stamford, CT. 
 
Paul Hadden commented, "The opening of our Boston office follows the success of HCR's San Francisco office opening in <TIMEX3 tid="t26" type="DATE" value="2015">2015</TIMEX3> and furthers our goal of strengthening local coverage and relationships in the key life science and R&D centers. <TIMEX3 tid="t28" type="DATE" value="PAST_REF">Recent</TIMEX3> data shows that Boston and the San Francisco / Bay Area each garnered about one-third of all biotech venture capital investment in <TIMEX3 tid="t27" type="DATE" value="2016">2016</TIMEX3> and it is important for us to continue to focus on these markets." 
 
About HealthCare Royalty Partners 
 
HCR is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage life science assets. HCR has $3.4 billion in cumulative capital commitments and is headquartered in Stamford, CT. Over <TIMEX3 tid="t29" type="DATE" value="200">the past decade</TIMEX3>, HCR's senior professionals have completed more than 60 healthcare investments. For more information, visit www.healthcareroyalty.com. 
 
>
</TimeML>
